Mesothelioma Cancer Centers
The University of Chicago Medicine Comprehensive Cancer Center
Doctors Affiliated with this Treatment Facility
Located on the South Side of Chicago, University of Chicago Medicine is an academic medical center on the campus of the University of Chicago, a private research university. The medical center includes Bernard A. Mitchell Hospital, an adult patient facility; Comer Children’s Hospital; Chicago Lying-in Hospital, a maternity and women’s hospital; Duchossois Center for Advanced Medicine, an ambulatory-care facility; the University of Chicago Pritzker School of Medicine, one of the top medical schools in the United States; and affiliated doctors offices and hospitals across the Chicago metro area.
While the University of Chicago was founded in 1892, it took several decades for dreams of a medical campus to be realized. In 1916, the university’s trustees set aside more than $5 million for the construction and endowment of a hospital, but World War I waylaid the process, and it was not completed until 1927. But once the University of Chicago Hospitals was dedicated on Halloween 1927, it wasted no time before expanding. The Home for Destitute and Crippled Children was added in 1928, and the Country Home for Convalescent Children and Chicago Lying-in Hospital were integrated within about a decade.
A tremendous period of growth followed in the 1950s and 1960s with the addition of cancer research centers, research laboratories, a children’s hospital, and other facilities. More recently, University of Chicago has added the Brain Research Pavilion, the Aeromedical Network, the Duchossois Center for Advanced Medicine, and the newest addition, University of Chicago Comer Children’s Hospital.
Since the founding of University of Chicago Medicine, history has been there made time and time again. A University of Chicago doctor discovered a way to preserve blood and established the first civilian blood bank. Sleep research began at the university in the late 1920s, when a doctor established the world’s first sleep laboratory. In the early 1930s, the University of Chicago opened one of the first nurseries for premature infants. Cancer research has also grown immeasurably inside the University of Chicago’s walls; hormone treatments, chemotherapy and genetic links to cancers have all been discovered or advanced by groundbreaking research there.
The University of Chicago Medicine Comprehensive Cancer Center treats patients with a variety of cancers, including malignant mesothelioma. UChicago uses a team-based approach to create personalized treatment plans for each patient.
Mesothelioma treatment at UChicago Medicine may include surgery, chemotherapy, radiation therapy or clinical trials for those who are eligible, with experience with heated intraperitoneal chemotherapy (HIPEC). They are also dedicated to developing and practicing emerging treatment methods to improve patient prognosis. New approaches to chemotherapy, immunotherapy and surgeries have been a primary focus.
The UChicago Medicine Comprehensive Cancer Center understands the struggles that patients and their families have when facing a mesothelioma diagnosis. As a result, they assign each patient with a nurse navigator to offer comprehensive support throughout their treatment journey.
- Emerging treatments
- American Nurses Credentialing Center Magnet Recognition
- Blue Cross and Blue Shield Distinction for Specialty Care
- Cellular therapy accreditation
- Joint Commission full accreditation
- National Cancer Institute Designated Comprehensive Cancer Center
- Top Teaching Hospital
Mesothelioma Clinical Trials at The University of Chicago Medicine Comprehensive Cancer Center
The following clinical trials are in progress or actively recruiting participants at The University of Chicago Medicine Comprehensive Cancer Center:
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Mesothelioma Last Updated: July 18, 2019 Status: Recruiting
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 18, 2019 Status: Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Solid Tumors; Malignant Pleural Mesothelioma; Gastric Adenocarcinoma; Colorectal Adenocarcinoma; Sarcoma Last Updated: July 17, 2019 Status: Recruiting
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Conditions: Cancer Last Updated: July 10, 2019 Status: Recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Conditions: Mesothelioma Last Updated: July 1, 2019 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
UChicago Medicine. Mesothelioma.